Is crp/albumin ratio (car) a new parameter to be added to risk stratification systems in metastatic renal cell carcinoma patients?

Simple item page
dc.contributor.authorUzun M.
dc.contributor.authorYildirim E.C.
dc.contributor.authorEkinci F.
dc.contributor.authorSemiz H.S.
dc.date.accessioned2024-07-22T08:03:58Z
dc.date.available2024-07-22T08:03:58Z
dc.date.issued2022
dc.description.abstractObjective: To evaluate the effect of pretreatment C-reactive protein (CRP)/Albumin ratio (CAR) on prognosis and its association with IMDC (International metastatic renal cell carcinoma database consortium) risk score and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients. Study Design: Descriptive study. Place and Duration of Study: Department of Medical Oncology, Dokuz Eylul University, Izmir, Turkey, between 2007 and 2020. Methodology: Clinico-pathological and treatment-related data of mRCC patients were retrospectively evaluated and included in the study. CAR was used as a prognostic inflammatory score. CAR threshold value for OS has been obtained by ROC analysis. The prognostic value of CAR was tested using Kaplan-Meier and Cox-regression models. IMDC-CAR model was created by adding CAR to IMDC risk stratification. Results: OS was 91 months in patients with CAR below the threshold value of 0.072 (0.072), while OS was 51 months in patients with CAR of 0.072 and above (p=0.005). According to IMDC risk stratification, intermediate and poor risk groups showed similar survival times (p0.05). However, when CAR was added to the IMDC risk score in the intermediate group, it was divided into 3 subgroups with different prognoses (p=0.02). Conclusion: CAR is an independent predictor of OS in mRCC patients. In this study, it has been demonstrated that more accurate prognosis prediction could be made by adding CAR to IMDC indicators in the intermediate risk group, which constitutes a highly heterogeneous group according to IMDC risk stratification. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.
dc.identifier.DOI-ID10.29271/jcpsp.2022.11.1425
dc.identifier.issn1022386X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12514
dc.language.isoEnglish
dc.publisherCollege of Physicians and Surgeons Pakistan
dc.rightsAll Open Access; Gold Open Access
dc.subjectC-Reactive Protein
dc.subjectCarcinoma, Renal Cell
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectRisk Assessment
dc.subjectalbumin
dc.subjectaxitinib
dc.subjectC reactive protein
dc.subjectnivolumab
dc.subjectprotein tyrosine kinase inhibitor
dc.subjectsunitinib
dc.subjectC reactive protein
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectC reactive protein to albumin ratio
dc.subjectcancer patient
dc.subjectcancer prognosis
dc.subjectcancer risk
dc.subjectcancer survival
dc.subjectcancer therapy
dc.subjectclinical feature
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectdisease association
dc.subjectevaluation study
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman cell
dc.subjectintermediate risk population
dc.subjectKaplan Meier method
dc.subjectlow risk population
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastatic renal cell carcinoma
dc.subjectmiddle aged
dc.subjectoncological parameters
dc.subjectoverall survival
dc.subjectproportional hazards model
dc.subjectreceiver operating characteristic
dc.subjectretrospective study
dc.subjectrisk assessment
dc.subjectsurvival time
dc.subjectTurkey (republic)
dc.subjectkidney tumor
dc.subjectpathology
dc.subjectprognosis
dc.subjectrenal cell carcinoma
dc.subjectrisk assessment
dc.titleIs crp/albumin ratio (car) a new parameter to be added to risk stratification systems in metastatic renal cell carcinoma patients?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu